eMedicine Specialties > Ophthalmology > Retina

Chorioretinopathy, Central Serous

Author: Kean Theng Oh, MD, Consulting Staff, Associated Retinal Consultants, PC
Coauthor(s): James Folk, MD, Professor, Department of Ophthalmology and Visual Science, University of Iowa College of Medicine
Contributor Information and Disclosures

Updated: Jul 16, 2007

Introduction

Background

Central serous chorioretinopathy (CSCR) is a disease in which a serous detachment of the neurosensory retina occurs over an area of leakage from the choriocapillaris through the retinal pigment epithelium (RPE). Other causes for RPE leaks, such as choroidal neovascularization, inflammation, or tumors, should be ruled out to make the diagnosis.

CSCR may be divided into 2 distinct clinical presentations. Classically, CSCR is caused by one or more discrete isolated leaks at the level of the RPE as seen on fluorescein angiography (FA). However, it is now recognized that CSCR may present with diffuse retinal pigment epithelial dysfunction (eg, diffuse retinal pigment epitheliopathy, chronic CSCR, decompensated RPE) characterized by neurosensory retinal detachment overlying areas of RPE atrophy and pigment mottling. During FA, broad areas of granular hyperfluorescence that contain one or many subtle leaks are seen.

Pathophysiology

Previous hypotheses for the pathophysiology have included abnormal ion transport across the RPE and focal choroidal vasculopathy. The advent of indocyanine green (ICG) angiography has highlighted the importance of the choroidal circulation to the pathogenesis of CSCR. ICG angiography has demonstrated both multifocal choroidal hyperpermeability and hypofluorescent areas suggestive of focal choroidal vascular compromise. Some investigators believe that initial choroidal vascular compromise subsequently leads to secondary dysfunction of the overlying RPE.

Studies employing multifocal electroretinography have demonstrated bilateral diffuse retinal dysfunction even when CSCR was active only in one eye. These studies support the belief of diffuse systemic effect on the choroidal vasculature.

Type A personalities, systemic hypertension, and obstructive sleep apnea may be associated with CSCR. The pathogenesis here is thought to be elevated circulating cortisol and epinephrine, which affect the autoregulation of the choroidal circulation.  Furthermore, Tewari et al demonstrated that patients with CSCR showed impaired autonomic response with significantly decreased parasympathetic activity and significantly increased sympathetic activity.1

Corticosteroids have a direct influence on the expression of adrenergic receptor genes and, thus, contribute to the overall effect of catecholamines on the pathogenesis of CSCR. Consequently, multiple studies have conclusively implicated the effect of corticosteroids in the development of CSCR. Carvalho-Recchia et al showed in a series that 52% of patients with CSCR had used exogenous steroids within 1 month of presentation as compared with 18% of control subjects.2

Cotticelli et al showed an association between Helicobacter pylori infection and CSCR.3 The prevalence of H pylori infection was 78% in patients with CSCR compared with a prevalence of 43.5% in the control group.  The authors proposed that H pylori infection may represent a risk factor in CSCR, though no further studies have substantiated this claim.

Mortality/Morbidity

Serous retinal detachments typically resolve spontaneously in most patients, with most patients (80-90%) returning to 20/25 or better vision. Even with return of good central visual acuity, many of these patients still notice dyschromatopsia, loss of contrast sensitivity, metamorphopsia, or, rarely, nyctalopia.

  • Patients with classic CSCR (characterized by focal leaks) have a 40-50% risk of recurrence in the same eye.
  • Risk of choroidal neovascularization from previous CSCR is considered small (<5%) but has an increasing frequency in older patients diagnosed with CSCR.
  • A subset of patients (5-10%) may fail to recover 20/30 or better visual acuity. These patients often have recurrent or chronic serous retinal detachments, resulting in progressive RPE atrophy and permanent visual loss to 20/200 or worse. The final clinical picture represents diffuse retinal pigment epitheliopathy.
  • Otsuka et al reviewed a subset of patients who presented with a severe variant of CSCR over a mean follow-up period of 10.6 years.4 These patients were characterized by multifocal lesions and bullous retinal detachments with shifting fluid and fibrin deposition. During the follow-up period, 52% of patients experienced recurrences of CSCR ranging from 1-5 episodes. However, 80.4% of eyes (n=46) returned to a visual acuity of better than 20/40 and 52% returned to a visual acuity of 20/20 or better. Eventually, patients reached a state of quiescent disease.

Race

CSCR appears uncommon among African Americans but may be particularly severe among Hispanics and Asians.

Sex

Classically, CSCR is most common in male patients aged 20-55 years with type A personality. This condition affects men 6-10 times more often than it affects women.

Age

Patients may present with a later age of onset (>50 y). Spaide et al reviewed 130 consecutive patients with CSCR and found the age range at first diagnosis to be 22.2-82.9 years, with a mean age of 49.8 years.5

  • Changes in the presentation and demographics of CSCR are observed with increasing age at first diagnosis. Classically, patients tend to be male and present with focal, isolated RPE leaks in one eye.
  • Patients diagnosed at 50 years or older are found to have bilateral disease, demonstrate a decreased male predominance (2.6:1), and show more diffuse RPE changes. Furthermore, these patients are more likely to have systemic hypertension or a history of corticosteroid use.

Clinical

History

  • Patients typically present with acute symptoms of visual loss and metamorphopsia (especially micropsia). Other symptoms include decreased central vision and a positive scotoma.
  • The decreased vision usually is improved by a small hyperopic correction.
  • Other clinical signs include a delayed retinal recovery time following photostress, loss of color saturation, and loss of contrast sensitivity.

Physical

  • Clinical exam shows a serous retinal detachment but no subretinal blood. The neurosensory retinal detachment may be very subtle, requiring contact lens exam for detection.
  • Pigment epithelial detachments, RPE mottling and atrophy, subretinal fibrin, and, rarely, subretinal lipid or lipofuscinoid flecks also may be seen.

Causes

Previous hypotheses for the pathophysiology have included abnormal ion transport across the RPE and focal choroidal vasculopathy. The advent of ICG angiography has highlighted the importance of the choroidal circulation to the pathogenesis of CSCR.

  • ICG angiography has demonstrated both multifocal choroidal hyperpermeability and hypofluorescent areas suggestive of focal choroidal vascular compromise. Some investigators believe that initial choroidal vascular compromise subsequently leads to secondary dysfunction of the overlying RPE.
  • Type A personalities and systemic hypertension may be associated with CSCR, presumably because of elevated circulating cortisol and epinephrine, which affect the autoregulation of the choroidal circulation.
  • Recent studies employing multifocal electroretinography have demonstrated bilateral diffuse retinal dysfunction even when CSCR was active only in one eye. This supports the belief of diffuse systemic effect on the choroidal vasculature.
  • Systemic associations of CSCR include organ transplantation, exogenous steroid use, endogenous hypercortisolism (Cushing syndrome), systemic hypertension, systemic lupus erythematosus, pregnancy, gastroesophageal reflux disease, use of sildenafil citrate, and use of psychopharmacologic medications.
    • Carvalho-Recchia et al showed in a series that 52% of patients with CSCR had used exogenous steroids within 1 month of presentation as compared with 18% of control subjects.2
    • Haimovici et al evaluated systemic risk factors for CSCR in 312 patients and 312 control subjects.6 Systemic steroid use (odds ratio [OR], 37.1) and pregnancy (OR, 7.1) were most strongly associated with CSCR. Other risk factors included antibiotic use, alcohol use, untreated hypertension, and allergic respiratory disorders.

More on Chorioretinopathy, Central Serous

Overview: Chorioretinopathy, Central Serous
Differential Diagnoses & Workup: Chorioretinopathy, Central Serous
Treatment & Medication: Chorioretinopathy, Central Serous
Follow-up: Chorioretinopathy, Central Serous
Multimedia: Chorioretinopathy, Central Serous
References
[ CLOSE WINDOW ]

References

  1. Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci. Aug 2006;47(8):3474-8. [Medline].

  2. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, Spaide RF, Freund KB, Rodriguez-Coleman H, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. Oct; 2002;109(10):1834-7. [Medline].

  3. Cotticelli L, Borrelli M, D'Alessio AC, Menzione M, Villani A, Piccolo G, et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. Mar-Apr 2006;16(2):274-8. [Medline].

  4. Otsuka S, Ohba N, Nakao K. A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina. Feb 2002;22(1):25-32. [Medline].

  5. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. Dec 1996;103(12):2070-9; discussion 2079-80. [Medline].

  6. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. Feb 2004;111(2):244-9. [Medline].

  7. Spaide RF. Deposition of yellow submacular material in central serous chorioretinopathy resembling adult-onset foveomacular vitelliform dystrophy. Retina. Apr 2004;24(2):301-4. [Medline].

  8. Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol. Jul 2006;90(7):869-74. Epub 2006 Apr 5. [Medline].

  9. Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. Apr 2006;22(2):145-9. [Medline].

  10. Nielsen JS, Weinreb RN, Yannuzzi L, Jampol LM. Mifepristone treatment of chronic central serous chorioretinopathy. Retina. Jan 2007;27(1):119-22. [Medline].

  11. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. Jun 2003;23(3):288-98. [Medline].

  12. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. Dec 2003;87(12):1453-8. [Medline].

  13. Penha FM, Aggio FB, Bonomo PP. Severe retinal thermal injury after indocyanine green-mediated photothrombosis for central serous chorioretinopathy. Am J Ophthalmol. May 2007;143(5):887-9. [Medline].

  14. Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging. Mar-Apr 2004;35(2):165-7. [Medline].

  15. Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol. Sep 1993;111(9):1229-33. [Medline].

  16. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology. Apr 1997;104(4):616-22. [Medline].

  17. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. Dec 2003;23(6):752-63. [Medline].

  18. Castro-Correia J, Coutinho MF, Rosas V, Maia J. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol. 1992;81(4):379-86. [Medline].

  19. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. Jun 2007;143(6):977-983. Epub 2007 Apr 24. [Medline].

  20. Costa RA, Scapucin L, Moraes NS, Calucci D, Melo LA, Cardillo JA, et al. Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy. Curr Eye Res. Nov 2002;25(5):287-97. [Medline].

  21. Cunningham ET Jr, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology. Dec 1996;103(12):2081-90. [Medline].

  22. Folk JC, Thompson HS, Han DP, Brown CK. Visual function abnormalities in central serous retinopathy. Arch Ophthalmol. Sep 1984;102(9):1299-302. [Medline].

  23. Gass JD. Central serous chorioretinopathy and white subretinal exudation during pregnancy. Arch Ophthalmol. May 1991;109(5):677-81. [Medline].

  24. Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology. May 1995;102(5):737-47. [Medline].

  25. Gass JDM. Stereoscopic Atlas of Macular Disease. 4th ed. 1997:52-70.

  26. Gomolin JE. Choroidal neovascularization and central serous chorioretinopathy. Can J Ophthalmol. Feb 1989;24(1):20-3. [Medline].

  27. Hooymans JM. Fibrotic scar formation in central serous chorioretinopathy developed during systemic treatment with corticosteroids. Graefes Arch Clin Exp Ophthalmol. Nov 1998;236(11):876-9. [Medline].

  28. Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol. Apr 1999;127(4):477-8. [Medline].

  29. Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. Ophthalmology. Oct 2002;109(10):1765-6. [Medline].

  30. Leveque TK, Yu L, Musch DC, Chervin RD, Zacks DN. Central serous chorioretinopathy and risk for obstructive sleep apnea. Sleep Breath. Apr 25 2007;[Medline].

  31. Mansuetta CC, Mason JO 3rd, Swanner J, Feist RM, White MF Jr, Thomley ML, et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol. Jun 2004;137(6):1096-100. [Medline].

  32. Marmor MF, Tan F. Central serous chorioretinopathy: bilateral multifocal electroretinographic abnormalities. Arch Ophthalmol. Feb 1999;117(2):184-8. [Medline].

  33. Matsunaga H, Nangoh K, Uyama M, Nanbu H, Fujiseki Y, Takahashi K. [Occurrence of choroidal neovascularization following photocoagulation treatment for central serous retinopathy]. Nippon Ganka Gakkai Zasshi. Apr 1995;99(4):460-8. [Medline].

  34. Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology. Dec 2005;112(12):2088-94. [Medline].

  35. Okushiba U, Takeda M. [Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography]. Nippon Ganka Gakkai Zasshi. Jan 1997;101(1):74-82. [Medline].

  36. Ozdemir H, Karacorlu SA, Senturk F, Karacorlu M, Uysal O. Assessment of macular function by microperimetry in unilateral resolved central serous chorioretinopathy. Eye. Aug 25 2006;[Epub ahead of print]. [Medline].

  37. Polak BC, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. Oct 1995;79(10):922-5. [Medline].

  38. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. Apr 1983;95(4):457-66. [Medline].

  39. Shukla D, Kolluru C, Vignesh TP, Karthikprakash S, Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye. May 26 2006;[Epub ahead of print]. [Medline].

  40. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol. Jun 2004;137(6):1073-80. [Medline].

  41. Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. Jul 1999;128(1):63-8. [Medline].

  42. Watzke RC, Burton TC, Leaverton PE. Ruby laser photocoagulation therapy of central serous retinopathy. I. A controlled clinical study. II. Factors affecting prognosis. Trans Am Acad Ophthalmol Otolaryngol. Mar-Apr 1974;78(2):OP205-11. [Medline].

  43. Watzke RC, Burton TC, Woolson RF. Direct and indirect laser photocoagulation of central serous choroidopathy. Am J Ophthalmol. Nov 1979;88(5):914-8. [Medline].

  44. Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina. 1987;7(2):111-31. [Medline].

  45. Yannuzzi LA, Freund KB, Goldbaum M, Scassellati-Sforzolini B, Guyer DR, Spaide RF, et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology. Apr 2000;107(4):767-77. [Medline].

  46. Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. Jun 1996;114(6):689-92. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

idiopathic central serous chorioretinopathy, central serous retinopathy, central serous chorioretinopathy, CSCR, choriocapillaris, retinal pigment epithelium, RPE, retinal pigment epithelium leaks, RPE leaks, RPE leakage, choroidal neovascularization, retinal pigment epithelial dysfunction, neurosensory retina

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Kean Theng Oh, MD, Consulting Staff, Associated Retinal Consultants, PC
Kean Theng Oh, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Society of Retina Specialists, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Coauthor(s)

James Folk, MD, Professor, Department of Ophthalmology and Visual Science, University of Iowa College of Medicine
James Folk, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, and American Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Brian A Phillpotts, MD, Former Vitreo-Retinal Service Director, Former Program Director, Clinical Assistant Professor, Department of Ophthalmology, Howard University College of Medicine
Brian A Phillpotts, MD is a member of the following medical societies: American Academy of Ophthalmology, American Diabetes Association, American Medical Association, and National Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Managing Editor

Steve Charles, MD, Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine
Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Club Jules Gonin, Macula Society, and Retina Society
Disclosure: Alcon Laboratories Consulting fee Consulting; OptiMedica Ownership interest Consulting

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.